It consists of a humanized IgG1κ monoclonal antibody targeting TROP2 (TACSTD2), a glycoprotein overexpressed in 80% of poor prognosis breast cancers, coupled to the topoisomerase I inhibitor SN-38 through a hydrolyzable linker. This evidence concerns the gene TACSTD2 and breast cancer.